Dielectric relaxation studies and dissolution behavior of amorphous verapamil hydrochloride

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 828-839

  Adrjanowicz, K ^a   Kaminski, K ^a   Paluch, M ^a   Wlodarczyk, P ^a   Grzybowska, K ^a   Wojnarowska, Z ^a   Hawelek, L ^a   Sawicki, W ^b   Lepek, P ^b   Lunio, R ^c  

^a UNIVERSITY OF SILESIA   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Pharmaceutical Works Polpharma SA   (Poland)

Author keywords

Broadband dielectric spectroscopy; Crystalline and amorphous forms; Dielectric relaxation; Dissolution rate; Glass transition; Solubility; Verapamil hydrochloride

Indexed keywords

VERAPAMIL;

ARTICLE; DIELECTRIC CONSTANT; DRUG SOLUBILITY; GLASS TRANSITION TEMPERATURE; MOLECULAR DYNAMICS;

EID: 74049164127     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21877     Document Type: Article

References (62)

1. Fukokova E, Makita M, Yamamura S. 1987. Glassy state of pharmaceuticals II. Bioinequivalence of glassy and crystalline indomethacin. Chem Pharm Bull 35:2943-2948.
2. Gupta P, Chawla G, Bansal AK. 2004. Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Mol Pharm 1:406-413.
3. Yamamoto K, Nakano M, Arita T, Takayama Y, Nakai Y. 1976. Dissolution behavior of phenytoin from a ground mixture with microcrystalline cellulose. J Pharm Sci 65:1484-1488.
4. Craig D, Royall P, Kett V, Hoptopn M. 1999. The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freze dried system. Int J Pharm 179:179-207.
5. Putheti R, Patil MC. 2009. Pharmaceutical formulation and development of Floating and Sellable sustained drug delivery systems: A review. e-J Sci Technol (e-JST) 4:1-12.
6. Gupta P, Bansal AK. 2005. Devitrification of amorphous celecoxib. AAPS PharmSciTech 6:Article 32.
7. Yoshioka M, Hancock BC, Zografi G. 1994. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83:1700.
8. Stubberud L, Forbes RT. 1998. The use of gravimetry for the study of the effect of additives on the moisture induced recrystallization of amorphous lactose. Int J Pharm 163:145-156.
9. Imaizumi H, Nambu N, Nagai T. 1980. Stability and physical properties of amorphous and crystalline forms of indomethacin. Chem Pharm Bull 28:2565-2569.
10. Zhou D, Geoff G, Zhang Z, Devalina L, Grant D, Schmitt EA. 2008. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm 5:927-936.
11. Martino P, Palmieri GF, Martelli S. 2008. Molecular mobility of paracetamol amorphous form. Chem Pharm Bull 48:1105-1108.
12. Aso Y, Yoshioka S, Kojima S. 2000. Relationship between the crystallization rates of amorphous nifedipine, phenobarbital and flopropione and their molecular mobility ad measured by their enthalpy relaxation and 1HNMR relaxation time. J Pharm Sci 89:408-416.
13. Makower B, Dye WB. 1956. Equilibrium moisture content and crystallization of amorphous sucrose and glucose. Agr Food Chem 4:72-77.
14. Johari GP, Kim S, Shanker RM. 2007. Dielectric relaxation and crystallization of ultraviscous melt and glassy states of Aspirin, Ibuprofen, Progesterone, and Quinidine. J Pharm Sci 96:1159-1175.
15. Keymolen B, Ford JL, Powell MW. 2003. Rajabi-Siahboomi AR, Investigation of the polymorphic transformations from glassy nifedipine. Thermochemica Acta 397:103-117.
16. Andronis V, Zografi G. 2000. Crystal nucleation and growth of indomethacin polymorphs from amorphous state. J Non-Cryst Solids 27:236-248.
17. Tombari E, Ferrari C, Johari GP, Shanker RM. 2008. Calorimetric relaxation in pharmaceutical molecular glasses and its utility in understanding their stability against crystallization. J Phys Chem B 112:10806-10814.
18. Andronis V, Zografi G. 1998. The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res 15:835-842.
19. Bhugra C, Pikal MJ. 2007. Role of thermodynamic, molecular, and kinetic factor in crystallization from amorphous state. J Pharm Sci 97:1329-1349.
20. Hancock BC, Shamblin SL, Zografi GJ. 1995. The molecular mobility of amorphous pharmaceutical solid below their glass transition temperatures. Pharm Res 12:799-806.
21. Alie J, Menegotto J, Cardon P, Duplaa H, Caron A, Lacabanne C, Bauer M. 2004. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. J Pharm Sci 93:218.
22. Carpentier L, Decressain R, Desprez S, Descamps M. 2006. Dynamics of the amorphous and crystalline alpha-, gamma-phases of indomethacin. J Phys Chem B 110:457-464.
23. Decamps M, Correia NT, Derollez P, Danede F, Capet F. 2005. Plastic and glassy crystal states of caffeine. J Phys Chem B 109:16092-16098.
24. Bras AR, Noronha JP, Antunes AMM, Cardoso MM, Schonhals A, Affouard F, Dionisio M, Correia NT. 2008. Molecular motions in amorphous Ibuprofen as studied by Broadband Dielectric Spectroscopy. J Phys Chem B 112:11087-11099.
25. Johari GP, Kim S, Shanker RM. 2005. Dielectric studies of molecular motion in amorphous solid and ultraviscous acetoaminphen. J Pharm Sci 94:2207-2223.
26. Vogelpoel H, Welnik J, Amidon G, Junginger H, Midha K, Moller H, Oling M, Shah V, Barends D. 2004. Biowaiver monographs for immediate realese solid oral dosage forms based on biopharmaceuticals classification system literature data: Verapamil hydrochloride, propanolol hydrochloride and atenolol. J Pharm Sci 93:1945-1956.
27. Kirsten R, Nelson K, Kirsten D, Heintz B. 1998. Clinical pharmacokinetics of vasodilators. Clin Pharm 34:457-482.
28. Rahman N, Najmul S, Azmi H. 2004. Spectrophotometric method for the determination of verapamil hydrochloride in pharmaceutical formulations using N-bromosuccinimide as oxidant. IL Farmaco 59:529-536.
29. Passerini N, Perissutti B, Albertini B, Voinovich D, Moneghini M, Rodriguez L. 2003. Controlled release of verapamil hydrochloride from waxy microparticles prepared by spray congealing. J Control Release 88:263-275.
30. Gonçalves-Araú jo T, Rajabi-Siahboomi Ali R, Caraballo I. 2008. Application of percolation theory in the study of an extended release verapamil hydrochloride formulation. Int J Pharm 361:112-117.
31. Dimitrov M, Lambov N. 1999. Study of Verapamil hydrochloride release from compressed hydrophilic Polyox-Wsr tablets. Int J Pharm 189:105-111.
32. Sawicki W. 2002. , Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur J Pharm Biopharm 53:29.
33. Eichelbaum M, Mikus G, Vogelgesang B. 1984. Pharmacokinetics of (+)-, (-)-, and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol 17:453-458.
34. Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M. 1984. Stereoselective first-pass metabolism of highly cleared drugs: Studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 18:733-740.
35. Product Information. 2005. Verelan® PM (verapamil hydrochloride). Schwarz Pharma, Milwaukee. WI, USA:
36. Rustichelli C, Gamberini MC, Ferioli V, Gamberini G. 1999. Properties of the racemic species of verapamil hydrochloride and gallopamil hydrochloride. Int J Pharm 178:111-120.
37. Macedo PB, Moynihan CT, Bose R. 1972. The role of ionic diffusion in polarisation in vitreous ionic conductors. Phys Chem Glasses 13:171-179.
38. Richert R, Wagner H. 1998. The dielectric modulus: Relaxation versus retardation. Solid State Ionics 105:167-173.
39. Williams G, Watts DC. 1970. Non-symmetrical dielectric relaxation behavior arising from a simple empirical decay function. Trans Faraday Soc 66:80-85;
40. Kohlrausch R. 1847. Nachtrag ü ber die elastiche Nachwirkung beim Cocon und Glasladen. Ann Phys (Leipzig) 72:393.
41. Ngai KL. 1998. Correlation between the secondary β-relaxation time at Tg with the Kohlrausch exponent of the primary α relaxation or the fragility of glass-forming materials. Phys Rev E57:7346.
42. Schneider U, Brand R, Lunkenheimer P, Loidl A. 2000. Excess wing in the dielectric loss of glass formers: A Johari-Goldstein b relaxation? Phys Rev Lett 84:5560-5563.
43. Vogel H. 1921. The law of the relation between the viscosity of liquids and the temperature. Physikalische Zeitschrift 22:645-646.
44. Fulcher G. 1925. Analysis of recent measurements of the viscosity of glasses. J Am Ceramic Soc 8:339-355.
45. Tammann G, HesseGöttingen W. 1926. Die Abhängigkeit der Viscositä t von der Temperatur bie unterkü hlten Flü ssigkeiten. Zeitschrift fü r anorganische und allgemeine Chemie, 156:245-257.
46. Psurek T, Hensel-Bielowka S, Ziolo J, Paluch M. 2002. Decoupling of the dc conductivity and a-struc-tural relaxation time in a fragile glass-forming liquid under high pressure. J Chem Phys 116: 9882-9888.
47. Salanne M, Simon C, Turq P. 2007. Conductivityviscosity-structure: Unpicking the relationship in an ionic liquid. J Phys Chem B 111:4678-4684.
48. Bhattacharyya S, Bagchi B. 1997. Decoupling of tracer diffusion from viscosity in a supercooled liquid near the glass transition. J Chem Phys 107:5852.
49. Angell CA. 1995. Formation of glasses from liquids and biopolymers. Science 267:1924.
50. Kim AI. 1998. The role of viscoelastic properties in physical stability of freeze-dried solids: Crystallization of mannitol. Purdue University AAT 9939376.
51. Johari GP. 1976. In: Goldstein M, Simba R, editors. The glass transition and nature of the glassy state. New York Acad Sci Annu 279: 117.
52. Johari GP, Goldstein M. 1971. Viscous liquids and the glass transition. III. Secondary relaxations in aliphatic alcohols and other nonrigid molecules. J Chem Phys 55:4245.
53. Okamoto N, Oguni M, Sagawa Y. 1997. Generation and extinction of a crystal nucleus below the glass transition temperature. J Phys Condens Mattr 9:9187.
54. Hikima T, Hanaya T, Oguni M. 1999. Microscopic observation of a peculiar crystallization in the glass transition region and b-process as potentially controlling the growth rate in triphenylethylene. J Mol Struct 479:245-250.
55. Hikima T, Hanaya T, Oguni M. 1996. b-Molecular rearrangement process, but not an a-process, as governing the homogeneous crystal-nucleation rate in a supercooled liquid. Bull Chem Soc Jpn 69:1863-1868.
56. Hikima T, Hanaya T, Oguni M. 1998. Numerical and morphological approach to the mechanism of homogeneous-nucleation-based crystallization in o-terphenyl. J Non-Cryst Solids 235-237:539-547.
57. Ngai KL, Rendell RW. 1997. Supercooled liquids, advances and novel applications (ACS Symposium Series 1997; vol. 676). In: Fourkas J T, Kivelson D, Mohanty U, Nelson K, editors. Supercooled liquids: Advances and novel applications. Washington, DC: American Chemical Society. chapter 4, p. 45.
58. Ngai KL, Tsang KY. 1999. Similarity of relaxation in supercooled liquids and interacting arrays of oscillators. Phys Rev E60:4511-4517.
59. Ngai KL. 2003. An extended coupling model description of the evolution of dynamics with time in supercooled liquids and ionic conductors. J Phys Condens Mat 15:S1107.
60. Ngai KL, Paluch M. 2004. Classification of secondary relaxation in glass-formers based on dynamic properties. J Chem Phys 120:857.
61. Kaminski K, Kaminska E, Adrjanowicz K, Grzybowiska K, Wlodarczyk P, Paluch M, Burian A, Ziolo J, Lepek P, Mazgalski J, Sawicki W. 2009. Dielectric relaxation studies on tramadol and its hydrochloride salt. J Pharm Sci (published online May 27, 2009).
62. Shamblin SL, Hancock BC, Dupuis Y, Pikal MJ. 1999. Interpretation of relaxation time constants for amorphous pharmaceutical system. J Pharm Sci 89:417-427.